Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Neoplasm Metastasis 1Gastrointestinal Diseases 1Digestive System Diseases 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Surveys and Questionnaires 16Bevacizumab 14Cisplatin 12Blood Specimen Collection 11Drug Therapy 10Standard of Care 9Nivolumab 9Gemcitabine 9Cetuximab 7pembrolizumab 6Specimen Handling 6S 1 (combination) 6Endoscopic Mucosal Resection 6Cyclophosphamide 6atezolizumab 5Sunitinib 5Radiotherapy 5Folfox protocol 5Educational Status 5Docetaxel 5fludarabine 4aldesleukin 4Radiosurgery 4Pemetrexed 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × IDRX-42 × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05489237 2026-05-04

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1 Recruiting
278 enrolled
GastrointestinalSarcoma

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡